Articles written by Vandana Singh - Benzinga

Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More

JP Morgan highlights 2025 growth prospects for biopharma, animal health, and specialty pharma stocks. Key picks include Eli Lilly, Zoetis, and Bristol-Myers Squibb.

Penny Stock Applied Therapeutics' FDA Troubles Trigger Investor Lawsuit, Shareholders Claim Deception Over Govorestat Clinical Data

Adrian Alexandru files a securities lawsuit against Applied Therapeutics, alleging the company misled investors about clinical trials for govorestat.

What's Going On With Amgen Stock On Friday?

Novo Nordisk's CagriSema shows 22.7% weight loss in Phase 3 trials, while tolerability concerns grow. MariTide offers competitive weight loss with less frequent dosing.

Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential

Rhythm Pharmaceuticals targets rare obesity disorders with its drug Imcivree, showing strong growth in sales and potential for significant market expansion

Boston Scientific Updates Instructions for Cryoablation Balloons After Reports Of Severe Injuries

Boston Scientific updates Polarx catheter guidelines due to atrio-esophageal fistula risks, highlighting safer usage practices after FDA approval.

Pyxis Oncology's Deprioritizes Second Pipeline Asset, Analyst Applauds Move

Pyxis Oncology prioritizes PYX-201 with promising Phase 1 results in solid tumors, while deprioritizing PYX-106 due to resource allocation and challenges.

Nebraska Attorney General Sues UnitedHealth Over Massive Data Breach That Disrupted Healthcare

Nebraska Attorney General sues UnitedHealth Group and affiliates over a data breach impacting 575,000 residents, alleging law violations and mishandled response.

Why Is Small Cap Galectin Therapeutics Stock Trading Lower On Friday?

Galectin Therapeutics' NAVIGATE trial shows belapectin reduces varices in MASH cirrhosis, but falls short of statistical targets; full data due in early 2025.

Why Is Cancer-Focused Aadi Bioscience Stock Trading Higher On Friday?

Aadi Bioscience secures ADC portfolio license, involving $44 million upfront and $805 million in milestones plus royalties.

Why Is Bioengineered Human Tissue-Focused Humacyte Stock Surging On Friday?

Humacyte's Symvess earns FDA approval as a first-in-class bioengineered vascular solution for urgent arterial injury repair in trauma cases.

FDA Approves Ionis Pharmaceuticals' Rare Genetic Disease Therapy to Lower High-Level Of Fat In Blood

Ionis' Tryngolza receives FDA approval for familial chylomicronemia syndrome, showing significant triglyceride reduction and fewer pancreatitis events.

Novo Nordisk's Hybrid Weight Loss Drug Falls Short On Expectations, Stock Plunges

Novo Nordisk's REDEFINE 1 trial shows CagriSema delivers significant weight loss and a favorable safety profile in obesity treatment.

Merck's Investigational Two-Drug Regime For HIV Meets Primary Goal In Two Late-Stage Trials

Merck shares Phase 3 trial results for its HIV-1 regimen, doravirine/islatravir, showing safety and comparable efficacy to existing therapies.

Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services

U.S. healthcare spending grew 7.5% to $4.9 trillion in 2023, with hospital care and prescription drugs driving costs. Private insurance accounted for 30% of total spending.

Why Is Vertex Pharmaceuticals Stock Trading Lower On Thursday After Back Pain Trial Data?

Vertex Pharmaceuticals' suzetrigine reduced pain in Phase 2 trials for lumbosacral radiculopathy. Plans for Phase 3 trials follow regulatory discussions.

Omeros Antibody Improves Overall Survival In Rare Complication After Stem Cell Transplant, Stock Surges

Omeros announces positive results from a pivotal narsoplimab trial in TA-TMA, showing significant survival benefits and advancing regulatory submissions.

Roche-Prothena Partnered Mid-Stage Parkinson's Trial Misses Primary Endpoint, But Cling On Signs Of Clinical Benefits

Prothena and Roche report Phase 2b PADOVA results on prasinezumab in Parkinson's, showing promising trends and nominal significance in key analyses.

FactSet Beats Q1 Earnings On Higher Subscriptions, Sticks to Annual Guidance

FactSet Q1 2025 sales rose 4.9% YoY to $568.7M. Adjusted EPS beat expectations at $4.37. FY25 revenue outlook reaffirmed at $2.285B–$2.305B.

Accenture Q1 Earnings: Revenue And EPS Beat Bolstered By Consulting And Managed Services, Raises Annual Revenue Outlook

Accenture surpasses Q1 FY2025 expectations with $17.69 billion in revenue and $3.59 EPS, driven by broad growth and $1.2 billion in generative AI bookings.

EXCLUSIVE: MIRA Pharmaceuticals Files FDA Application To Start Human Trials For Its Lead Pain Treatment

MIRA Pharmaceuticals submits an IND for Ketamir-2, aiming to treat neuropathic pain with 100% pain reversal shown in preclinical studies.